BioNTech SE (BNTX) Reports Q4 EPS of EUR12.18

BioNTech SE (NASDAQ: BNTX) reported Q4 EPS of EUR12.18. Revenue for the quarter came in at EUR5.53 billion.

Estimated BioNTech COVID-19 vaccine revenues for the full 2022 financial year €13 billion - €17 billion

For earnings history and earnings-related data on BioNTech SE (BNTX) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• Nike names former Pfizer CFO David Denton as new finance chief